A committee of the European Medicines Agency has recommended approving Uplizna (inebilizumab-cdon) for adults with neuromyelitis optica spectrum disorder (NMOSD) who test positive for aquaporin-4 water channel autoantibodies (AQP4-IgG). This recommendation from the Committee for Medicinal Products for Human Use, known as CHMP, will now be reviewed by…
AQP4 autoantibodies
Recent Posts
- How to help people in your social circle better understand chronic illness
- New NMOSD study points to silent brain changes between relapses
- Working with a pain management clinic feels like a new world of possibility
- My summer vacation tips for traveling with NMOSD
- NMOSD patients face spinal cord shrinkage even absent relapses